153 related articles for article (PubMed ID: 26843614)
1. Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis.
De Toni EN; Ziesch A; Rizzani A; Török HP; Hocke S; Lü S; Wang SC; Hucl T; Göke B; Bruns C; Gallmeier E
Oncotarget; 2016 Feb; 7(8):9477-90. PubMed ID: 26843614
[TBL] [Abstract][Full Text] [Related]
2. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
van der Heijden MS; Brody JR; Dezentje DA; Gallmeier E; Cunningham SC; Swartz MJ; DeMarzo AM; Offerhaus GJ; Isacoff WH; Hruban RH; Kern SE
Clin Cancer Res; 2005 Oct; 11(20):7508-15. PubMed ID: 16243825
[TBL] [Abstract][Full Text] [Related]
3. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
4. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
6. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
[TBL] [Abstract][Full Text] [Related]
7. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Wang S; El-Deiry WS
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705
[TBL] [Abstract][Full Text] [Related]
8. TRAIL receptor signaling and therapeutics.
Abdulghani J; El-Deiry WS
Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
[TBL] [Abstract][Full Text] [Related]
9. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
10. TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of
Ben Khaled N; Hammer K; Ye L; Alnatsha A; Widholz SA; Piseddu I; Sirtl S; Schneider J; Munker S; Mahajan UM; Montero JJ; Griger J; Mayerle J; Reiter FP; De Toni EN
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358659
[TBL] [Abstract][Full Text] [Related]
11. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
[TBL] [Abstract][Full Text] [Related]
13. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
Qiu Y; Liu X; Zou W; Yue P; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4973-80. PubMed ID: 17510428
[TBL] [Abstract][Full Text] [Related]
14. Targeting TRAIL in the treatment of cancer: new developments.
Lim B; Allen JE; Prabhu VV; Talekar MK; Finnberg NK; El-Deiry WS
Expert Opin Ther Targets; 2015; 19(9):1171-85. PubMed ID: 26004811
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
[TBL] [Abstract][Full Text] [Related]
16. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
Wang S
Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
[TBL] [Abstract][Full Text] [Related]
17. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.
Dai X; Zhang J; Arfuso F; Chinnathambi A; Zayed ME; Alharbi SA; Kumar AP; Ahn KS; Sethi G
Exp Biol Med (Maywood); 2015 Jun; 240(6):760-73. PubMed ID: 25854879
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.
Gallmeier E; Hucl T; Brody JR; Dezentje DA; Tahir K; Kasparkova J; Brabec V; Bachman KE; Kern SE
Cancer Res; 2007 Mar; 67(5):2169-77. PubMed ID: 17332347
[TBL] [Abstract][Full Text] [Related]
19. Targeting death-receptors in radiation therapy.
Niemöller O; Belka C
Results Probl Cell Differ; 2009; 49():219-39. PubMed ID: 19582410
[TBL] [Abstract][Full Text] [Related]
20. The BRCA2 gene is a potential molecular target during 5-fluorouracil therapy in human oral cancer cells.
Nakagawa Y; Kajihara A; Takahashi A; Kondo N; Mori E; Kirita T; Ohnishi T
Oncol Rep; 2014 May; 31(5):2001-6. PubMed ID: 24627042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
